Translate Bio, Inc. (TBIO) News

Translate Bio, Inc. (TBIO): $0.90

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add TBIO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#313 of 329

in industry

Filter TBIO News Items

TBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TBIO News From Around the Web

Below are the latest news stories about TELESIS BIO INC that investors may wish to consider to help them evaluate TBIO as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers that are worth watching on Monday morning!

William White on InvestorPlace | November 27, 2023

Telesis Bio Reports Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. “This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team,” said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengt

Yahoo | November 13, 2023

Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio’s website at https://ir.telesisbio.com/. About Telesis BioTelesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled

Yahoo | November 7, 2023

Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA

New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in daysSAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® De novo Cloning and Amplification kit on the BioXp 3250 and BioXp 9600 systems. This cell-free DNA amplification kit provides an efficient automated solution for building and amplifying DNA constructs to transfecti

Yahoo | November 3, 2023

Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS

New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology WorkstationSAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® NGS Library Prep kit for Whole Genome Sequencing on the BioXp 3250 and BioXp 9600 systems. This NGS libr

Yahoo | September 28, 2023

This Telesis Bio Insider Increased Their Holding In The Last Year

Insiders were net buyers of Telesis Bio, Inc.'s ( NASDAQ:TBIO ) stock during the past year. That is, insiders bought...

Yahoo | September 5, 2023

Telesis Bio Appoints William J. Kullback Chief Financial Officer

SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. “Bill’s deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to

Yahoo | August 29, 2023

Telesis Bio Reports Second Quarter 2023 Financial Results

-- Total revenue of $8.7M in 2QFY23 - increased by 53% year over yearSAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023. “We achieved important milestones this quarter toward our path to profitability by delivering revenue growth again while expanding gross margins and reducing operating expenses. In addition, we raised capital during the qu

Yahoo | August 10, 2023

Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The pres

Yahoo | August 3, 2023

Telesis Bio to Present at Jefferies Healthcare Conference 2023

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time. The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.telesisbio.com/news-events/events. The r

Yahoo | June 8, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!